What do systematic reviews say?

Psychosocial interventions vs treatment

The review found no eligible studies for this question.

• Psychosocial interventions for stimulant use disorder 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Psychosocial interventions vs no intervention

Summary of findings table ‐ Any psychosocial intervention probably leads to higher continuous abstinence, end of treatment compared with no intervention (moderate certainty).

• Psychosocial interventions for stimulant use disorder 2024 · Cochrane Headline outcomes only
  RR 1.89 [1.2, 2.97]
  12 studies · 1770 participants
  Moderate

Psychosocial interventions vs no intervention

Summary of findings table ‐ Any psychosocial intervention showed no clear difference in continuous abstinence, longest compared with no intervention (low certainty).

• Psychosocial interventions for stimulant use disorder 2024 · Cochrane Headline outcomes only
  RR 1.14 [0.85, 1.54]
  3 studies · 266 participants
  Low

Psychosocial interventions vs treatment

Summary of findings table ‐ Any psychosocial intervention may leads to higher number of continuously abstinent women ‐ total compared with treatment (low certainty).

• Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy 2024 · Cochrane Headline outcomes only
  RR 1.34 [1.14, 1.57]
  3 studies · 378 participants
  Low

Combined low‐dose OCP vs another combined low‐dose OCP

Combined low‐dose OCP may leads to higher adverse events for continuous vs standard regimen OCP compared with another combined low‐dose OCP (low certainty).

• Combined oral contraceptive pill for primary dysmenorrhoea 2023 · Cochrane Headline outcomes only
  RR 1.11 [1.01, 1.22]
  3 studies · 602 participants
  Low

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 269 participants
  Moderate

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Corticosteroids vs placebo

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 240 participants
  Very low